| Autor: |
Dolzhenko MM; The Cardiology Department, The Shupyk National Medical Academy of Postgraduate Education, Dorogozhytska St., 9, Kyiv, 04112, Ukraine. marynadolzhenko@gmail.com., Barnett OY; Department of Therapy № 1 of Medical Diagnostics, Hematology and Transfusiology, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine., Grassos C; The Cardiology Department, General Hospital of Attica 'KAT', Kifissia, Greece., Dragomiretska NV; The Medical Rehabilitation Department, SI 'Ukrainian Scientific-Research Institute of Medical Rehabilitation and Balneology of the Ministry of Health of Ukraine', Kiev, Ukraine., Goloborodko BI; The Cardiology Department, ODREX Medical Home, Rozkidaylivska Street, 69/71, Odesa, 65080, Ukraine., Ilashchuk TO; The Propedeutics of Internal Diseases Department, Higher State Educational Establishment of Ukraine 'Bukovinian State Medical University', Chernivtsi, Ukraine., Zuiev KO; The General Endocrine Pathology and Metabolism Department, Kyiv Municipal Endocrine Center, Kiev, Ukraine., Karpenko OV; Department of propedeutics of internal medicine № 2, Bohomolets National Medical University, Kiev, Ukraine., Kolesnikova OV; Aging and the Metabolic Associated Diseases Prevention Research Department, Government Institution 'L.T. Malaya Therapy National Institute of the National Academy of Medical Sciences of Ukraine', Kharkiv, Ukraine., Kolesnyk TV; The Department of Internal Medicine Propedeutics, State Institution 'Dnipropetrovsk Medical Academy' of the Ministry of Health of Ukraine, Dnipro, Ukraine., Talaieva TV; The Department of Clinical Physiology and Genetics, National Scientific Center, M.D. Strazhesko Institute of Cardiology, Kiev, Ukraine., Vakaliuk IP; The Department of Internal Medicine No. 2 and Nursing, State Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine., Tiabut TD; The Cardiology and Rheumatology Department, Belarusian Medical Academy of Postgraduate Education, Minsk, Belarus., Mesnikova IL; Polyclinic Therapy Department, Belarusian State Medical University, Minsk, Belarus., Zinych OV; The Age Endocrinology and Clinical Pharmacology Department, State Institution V.P. Komisarenko Institute of Endocrinology and Metabolism of NAMS of Ukraine, Kiev, Ukraine. |
| Abstrakt: |
Cardiovascular diseases (CVDs) are the leading cause of premature deaths globally and in Ukraine. Dyslipidemia is a recognized risk factor for the development of CVD. Therefore, early detection and appropriate management of dyslipidemia are essential for the primary prevention of CVDs. However, currently, there is a lack of Ukraine-specific guideline recommendations focusing on the management of dyslipidemia in individuals with low-to-moderate CV risk, thus creating an urgent need for structured and easily implementable clinical recommendations/guidelines specific to the country. An expert panel of cardiologists, endocrinologists, and family physicians convened in Ukraine in March 2019. The expert panel critically reviewed and analyzed the current literature and put forth the following recommendations for the management of dyslipidemia in individuals with low-to-moderate risk of CVDs specific to Ukraine: (1) family physicians have the greatest opportunities in carrying out primary prevention; (2) lipid-lowering interventions are essential for primary prevention as per guidelines; (3) a number of nutraceuticals and nutraceutical combinations with clinically established lipid-lowering properties can be considered for primary prevention; they also have a suggested role as an alternative therapy for statin-intolerant patients; (4) on the basis of clinical evidence, nutraceuticals are suggested by guidelines for primary prevention; (5) red yeast rice has potent CV-risk-lowering potential, in addition to lipid-lowering properties; (6) in patients with low-to-moderate cardiovascular risk, a nutraceutical combination of low-dose red yeast rice and synergic lipid-lowering compounds can be used as integral part of guideline-recommended lifestyle interventions for effective primary prevention strategy; (7) nutraceutical combination can be used in patients aged 18 to 75+ years; its use is particularly appropriate in the age group of 18-44 years; (8) it is necessary to attract the media (websites, etc.) to increase patient awareness on the importance of primary prevention; and (9) it is necessary to legally separate nutraceuticals from dietary supplements. These consensus recommendations will help physicians in Ukraine effectively manage dyslipidemia in individuals with low-to-moderate CV risk. |
Full text from SpringerLink